McFarlane Neil F. — SEC insider filings

SEC reporting owner CIK 1681098. 15 insider filings on record with FilingPulse; latest filed 2026-10-13.

Transaction summary — filings shown

Covers all 15 filings on record, filed 2021-03-03 to 2026-10-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ZEVRA THERAPEUTICS, INC. (ZVRA)President and CEO, Director9—6 legs · 236,942 sh · $2,141,85717
Adamas Pharmaceuticals Inc (ADMS)Chief Executive Officer, Director2——5
COLLEGIUM PHARMACEUTICAL, INC (COLL)Director4——4

Insider filings — McFarlane Neil F.

FiledFormIssuerReported transactionsSource
2026-10-134ZEVRA THERAPEUTICS, INC. (ZVRA)Option exercise (M): 50,000 · Sale (S): 20,000 @ $11.25 · Option exercise (M): 50,000 (derivative) @ $0EDGAR
2026-02-104ZEVRA THERAPEUTICS, INC. (ZVRA)Option exercise (M): 37,500 · Sale (S): 14,625 @ $8.56 · Option exercise (M): 37,500 (derivative) @ $0EDGAR
2026-02-024ZEVRA THERAPEUTICS, INC. (ZVRA)Option exercise (M): 233,334 · Sale (S): 91,000 @ $9.38 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 · Option exercise (M): 233,334 (derivative) @ $0EDGAR
2025-10-104ZEVRA THERAPEUTICS, INC. (ZVRA)Option exercise (M): 50,000 · Sale (S): 19,500 @ $10.82 · Option exercise (M): 50,000 (derivative) @ $0EDGAR
2025-02-144ZEVRA THERAPEUTICS, INC. (ZVRA)Sale (S): 61,273 @ $7.86 · Sale (S): 30,544 @ $8.05EDGAR
2025-02-104ZEVRA THERAPEUTICS, INC. (ZVRA)Grant/award (A): 225,000 (derivative) @ $0 · Grant/award (A): 112,500 (derivative) @ $0EDGAR
2025-02-034ZEVRA THERAPEUTICS, INC. (ZVRA)Option exercise (M): 233,333 · Option exercise (M): 233,333 (derivative) @ $0EDGAR
2024-05-164COLLEGIUM PHARMACEUTICAL, INC (COLL)Grant/award (A): 7,693 @ $0EDGAR
2024-02-024ZEVRA THERAPEUTICS, INC. (ZVRA)Grant/award (A): 700,000 (derivative) @ $0EDGAR
2023-10-114ZEVRA THERAPEUTICS, INC. (ZVRA)Grant/award (A): 600,000 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0EDGAR
2023-05-194COLLEGIUM PHARMACEUTICAL, INC (COLL)Grant/award (A): 9,792 @ $0EDGAR
2022-05-234COLLEGIUM PHARMACEUTICAL, INC (COLL)Grant/award (A): 14,035 @ $0EDGAR
2022-04-084COLLEGIUM PHARMACEUTICAL, INC (COLL)Grant/award (A): 17,845 @ $0EDGAR
2021-11-244Adamas Pharmaceuticals Inc (ADMS)Grant/award (A): 75,000 @ $0 · Code (U): 600,000 · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 200,000 (derivative)EDGAR
2021-03-034Adamas Pharmaceuticals Inc (ADMS)Grant/award (A): 300,000 @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-03-03 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1681098 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs